StockIQpro
NASDAQ:CGEM

Cullinan Therapeutics, Inc.

Track all markets on TradingView
Track all markets on TradingView

Cullinan Therapeutics, Inc. reported net income of −$219.9M in fiscal 2025. Free cash flow was −$175.8M.Summary generated from Cullinan Therapeutics, Inc.'s SEC filings. Latest annual report filed Mar 10, 2026.

Key statistics

Fiscal 2025 from SEC filings. Methodology
Revenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−44.0%
Debt / equityn/a
Free cash flow−$175.8M
FCF marginn/a
Share count changen/a

Financials

Fiscal years, $M
Item20212022202320242025
Revenue190n/an/an/a
Operating income−68145−191−197−242
Net income−66111−153−167−220
Free cash flow−43−128−134−145−176

Recent filings

From SEC EDGAR

Peers

Biological products, (no diagnostic substances)